Reneo Pharmaceuticals (NASDAQ:RPHM) Upgraded by Zacks Investment Research to Hold

Reneo Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Reneo Pharmaceuticals Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Reneo Pharmaceuticals (NASDAQ:RPHM) Upgraded by Zacks Investment Research to Hold